Laurel Wealth Advisors LLC Has $898,000 Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Laurel Wealth Advisors LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 3.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 4,572 shares of the medical research company’s stock after purchasing an additional 140 shares during the quarter. Laurel Wealth Advisors LLC’s holdings in IQVIA were worth $898,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of IQV. FMR LLC grew its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after buying an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of IQVIA during the third quarter valued at approximately $147,683,000. JPMorgan Chase & Co. raised its position in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Nordea Investment Management AB grew its position in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the period. Finally, 1832 Asset Management L.P. increased its stake in IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after purchasing an additional 376,595 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on IQV shares. Bank of America dropped their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Leerink Partners reissued an “outperform” rating and set a $248.00 price objective (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Barclays reduced their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, Royal Bank of Canada restated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $255.82.

IQVIA Stock Performance

NYSE IQV opened at $198.12 on Wednesday. The firm has a market cap of $35.96 billion, a price-to-earnings ratio of 26.00, a PEG ratio of 2.05 and a beta of 1.48. The company has a 50-day simple moving average of $201.43 and a two-hundred day simple moving average of $221.61. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.